Related references
Note: Only part of the references are listed.The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis
John Foley et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Pharmacodynamics of natalizumab extended interval dosing in MS
Lana Zhovtis Ryerson et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Preference for Subcutaneous Injection or Intravenous Infusion of Biological Therapy Among Italian Patients With SLE
Marina Falanga et al.
JOURNAL OF PATIENT EXPERIENCE (2019)
A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis
Tatiana Plavina et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
CD4 cell response to interval therapy with natalizumab
Regina Berkovich et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
Helmut Butzkueven et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study
Robert J. Fox et al.
NEUROLOGY (2014)
Subcutaneous Versus Intravenous Bortezomib: Efficiency Practice Variables and Patient Preferences
Meagan S. Barbee et al.
ANNALS OF PHARMACOTHERAPY (2013)
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Xavier Pivot et al.
LANCET ONCOLOGY (2013)
Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study
Nicola De Stefano et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2012)
MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis
Luigi M. E. Grimaldi et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
A. Kerbrat et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Observations during an elective interruption of natalizumab treatment: a post-marketing study
Giovanna Borriello et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Natalizumab Drug Holiday in Multiple Sclerosis: Poorly Tolerated
Joep Killestein et al.
ANNALS OF NEUROLOGY (2010)
Considerations on Discontinuing Natalizumab for the Treatment of Multiple Sclerosis
Joseph R. Berger et al.
ANNALS OF NEUROLOGY (2010)
Natalizumab Dosage Suspension: Are We Helping or Hurting?
Timothy W. West et al.
ANNALS OF NEUROLOGY (2010)
Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria
P. O'Connor et al.
MULTIPLE SCLEROSIS (2009)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
